SERIOUS ILLNESS · MYLIFE.IE EDITORIAL · NOVEMBER 2026
Same policy, same premium — different value
Since 2012, EU law has required men and women to pay identical premiums for identical cover. Our research finds that in Irish serious illness cover, the identical premium does not buy identical expected value — and that the answer for buyers is not price, but definitions.
By Donal Milmo-Penny QFA FLIA · Research Lead · November 2026
Aoife and Mark are both 38. They take out serious illness cover on the same day, with the same office, for the same sum — €150,000 each — on the same policy conditions. Their premiums are identical, to the cent.
The identical premiums are not a coincidence and not a commercial decision. They are the law, and they have been since 21 December 2012. What the law equalised is the price. What it could not equalise is what the price buys — and our latest working paper set out to measure the difference.
Where the identical premium came from
Until 2012, insurers across Europe priced by sex, because the risks being insured differ by sex: men and women die at different rates, at different ages, of different things, and fall seriously ill on different patterns. Charging each group its own actuarial cost was ordinary insurance practice.
The EU Gender Directive permitted that practice to continue — until Belgium's Test-Achats consumer association challenged the exemption, and in March 2011 the Court of Justice of the EU struck it down. From the end of 2012, sex could no longer be used as a rating factor in new insurance contracts anywhere in the Union. The court's reasoning was about equality, and it was straightforward: pricing an individual by their sex treats them as a category, not a person, and equal treatment of men and women is a foundational principle of EU law that an indefinite actuarial carve-out could not override.
Nothing in this article quarrels with that ruling, and nothing in it suggests any insurer is doing anything wrong. Irish offices charge Aoife and Mark the same premium because they must. But a rule that equalises premiums does not, and cannot, equalise the underlying risks — it averages them. And whenever two groups with different expected claims pay one blended price, one group is paying above its own actuarial cost and the other below it. The question our research asked is simply: in Irish serious illness cover, which way does it run, and by how much?
What the research found
Our working paper on serious illness fair value approached the market the way an actuary would rather than the way a price-comparison site does. Serious illness cover pays on a contractual definition, not on a diagnosis alone — a policy pays for the heart attack, stroke or cancer that meets its wording, which differs office by office. The paper mapped each domestic office's policy conditions to a common disease classification, then valued those conditions against independently sourced Irish incidence data for ten representative lives, producing a fair-value index: the expected benefit a buyer receives for the premium they pay.
Two findings frame everything else. The index varies across offices by several times more than premium does — the market range for an average buyer runs from 0.24 to 0.93 — and no office leads across the whole age range. Value, not price, is where Irish serious illness products genuinely differ.
The third finding is the one this article is about. Running each representative life through the same contracts at the same unisex premiums, an identical policy at an identical premium delivers less expected benefit to a woman than to a man. Depending on the office and the age, the gap in the fair-value index runs from 0.05 to 0.28. At its widest, the difference between what the same premium buys Aoife and what it buys Mark is comparable to a large share of the entire spread between the strongest and weakest products on the market.
The mechanism is arithmetic, not conduct. The conditions serious illness policies cover occur at different rates in men and women across the age range, and once a single premium must serve both, the expected value per euro cannot be equal for both. The Test-Achats ruling moved the difference between the sexes out of the premium column. It did not, because no pricing rule could, remove it from the claims experience.
The same coin, flipped elsewhere
Fairness requires saying that the direction of this subsidy is a property of the product, not of the industry.
In life cover, women's lower mortality means a unisex premium sits above their own actuarial cost — the same structural position as in serious illness. In annuities, it reverses: women's longer lives mean a unisex annuity rate pays them a better income relative to actuarial cost, funded by the shorter-lived. Across a lifetime of financial products, the subsidies run in both directions, which is much of why the court was comfortable requiring them. Anyone presenting unisex pricing as a one-way transfer is reading one product and stopping.
But buyers do not purchase a lifetime average. They purchase one product at a time, and a woman buying serious illness cover is buying the product where the structure runs against her. She cannot negotiate the premium — nobody can — which makes the one variable she does control matter more, not less.
What Aoife controls
Not the price. The definitions.
Since every office must quote her the same premium basis it quotes Mark, and since the fair-value index varies across offices by several times more than premium does, the decision that determines what Aoife's €150,000 of cover is actually worth is which office's policy conditions she buys — assessed at her age and against her incidence, not the market's average. The paper's finding that no office leads across the whole age range means there is no shortcut here: the best-value contract for a 38-year-old woman is not reliably the best-value contract for a 55-year-old man, or even for a 48-year-old woman. A recommendation that doesn't know who is asking isn't a recommendation.
This is also, for what it's worth, the answer to the reasonable question the research provokes — *should she buy it at all?* The product is real: across the five domestic offices, more than €919 million was paid in protection claims in 2025, across more than 18,200 individual claims. But our claims research shows the same pattern from the other end: life cover paid rates cluster tightly at 97–99% while the meaningful differences between offices sit in specified serious illness — the same territory, definitions and conditions, where the fair-value gaps live. Serious illness cover is worth owning. It is the last product in the Irish protection market that should be bought on price.
The disclosure point
There is a policy observation worth making, calmly. The premium equality the law delivers is visible on every quote; the value inequality that survives it is visible nowhere. A market that must charge everyone the same price, but is under no obligation to show anyone the expected value behind that price, has moved the difference between buyers from a column consumers could see into one they cannot. The remedy is not repricing — that door is closed, rightly or wrongly, by European law. It is measurement and disclosure: putting fair value alongside premium, which is precisely what the working paper exists to do, and what we would welcome any office or regulator taking further.
The full methodology — the disease classification mapping, the ten representative lives, and the office-by-office index — is in *Serious Illness Cover in Ireland: claims, definitions and fair value for consumers*, free to download. If you want the analysis run for your own age and circumstances rather than a representative life, that is what a whole-of-market review is for: every case reviewed by a QFA, no obligation, and the comparison done on definitions, not price.
About the author
Research Lead at mylife.ie. More than twenty years' experience in Irish financial services, protection and client advisory work. Qualified Financial Adviser (QFA) and Fellow of the Life Insurance Association (FLIA). Former Chairman of PIBA and Director of Brokers Ireland.
Market Coverage
5 of 5
Every Irish life office
Author
QFA FLIA
20+ yrs experience
Regulation
Central Bank
SMP Financial
Talk to mylife
mylife.ie compares life insurance, mortgage protection and serious illness cover across all five Irish life offices. Every case is reviewed by a QFA. Start a conversation at mylife.ie or drop us a call.
Sources
- Fair-value index range (0.24–0.93, average buyer), male–female value gap (0.05–0.28), ten representative lives, no office leading across the age range, index varying across offices by several times more than premium: MWP-2026-05
- Claims paid 2025 (€919m+, 18,200+ claims), life-cover paid rates 97–99%, differences concentrated in specified serious illness: MCR-2025
- Unisex pricing requirement: Council Directive 2004/113/EC; CJEU, Case C-236/09 Association belge des Consommateurs Test-Achats (1 March 2011); unisex rule effective for new contracts from 21 December 2012
Donal Milmo-Penny QFA FLIA is Research Lead at mylife.ie and author of the mylife.ie Working Paper Series. This article is for information only and does not constitute regulated financial advice. SMP Financial Ltd t/a mylife.ie is regulated by the Central Bank of Ireland (C42382).
